Remote Programming of Cardiac Implantable Electronic Device (REACT)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Sylvain MD Ploux
- Phone Number: +33 (0)5 57 65 64 71
- Email: sylvain.ploux@chu-bordeaux.fr
Study Contact Backup
- Name: Estel HUGOT
- Phone Number: +33 (0)5 57 62 32 26
- Email: estel.hugot@chu-bordeaux.fr
Study Locations
-
-
France
-
Pessac, France, France, 33604
- Bordeaux University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient of both sexes over the age of 18
- Patients implanted with a cardiac pacemaker or an automatic defibrillator and an indication for device check-up (interrogation ± programming) which may be periodic as part of their follow-up, postoperative, following a remote monitoring alert, pre/post MRI or following symptoms.
- Person beneficiary of social security insurance.
- Informed consent confirmed in writing (at the latest on the day of inclusion and before any examination required by the research).
- Women of procreating age with effective contraception
Exclusion Criteria:
- Patients younger than 18 years old
- Patients who are incapable to understand the study design or to give informed consent.
- Pregnant or breastfeeding women
- Persons placed under judicial protection, curatorship, tutorship.
- Subject deprived of liberty on judicial or administrative decision
- Persons participating in another study who are still in their period of exclusion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CIED's interrogation/programming
All the patients will be included in this single arm to interrogate/programm their CIED
|
As the study investigates remote programming, we will describe two locations: local (patient side) and remote (expert side).
Local support is defined by a physician or a technician under the direct responsibility of a nearby physician who connect the patient to the remote programming system.
Similar to a conventional check-up, an external defibrillator will be located in the near vicinity of the patient.
The patient will first be connected to the programmer as during a conventional follow-up.
The programmer will then be connected to a local PC which captures the programmer VGA video output and controls the programmer through a mouse emulator.
This local PC will be remotely controlled by the remote PC using Cisco Webex, a communication software used worldwide to support telemedicine.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Successful remote interrogation and programming of CIED
Time Frame: 18 months
|
Success rate of remote interrogation and programming of CIED
|
18 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To assess the user-friendliness of the system (1)
Time Frame: 18 months
|
Time of the procedure (interrogation and programming)
|
18 months
|
|
To assess the user-friendliness of the system (2)
Time Frame: 18 months
|
Type of programming modifications done
|
18 months
|
|
To assess the user-friendliness of the system (3)
Time Frame: 18 months
|
Time of intallation procedure
|
18 months
|
|
To assess the user-friendliness of the system (4)
Time Frame: 18 months
|
Turnaround time of the command
|
18 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sylvain MD Ploux, University Hospital, Bordeaux
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- CHUBX 2021/07
- 2021-A00885-36 (Other Identifier: ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.